CLSN Celsion Corporation

0.23
-3.11  -93%
Previous Close 3.34
Open 0.24
Price To book 30.39
Market Cap 13.11M
Shares 56,982,000
Volume 892,806
Short Ratio 1.99
Av. Daily Volume 2,061,680

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Failed to meet primary endpoint. New Phase 3 trial initiated, with enrollment to be completed early 2018 with first interim efficacy endpoint due 4Q 2018.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 1b interim data released January 17, 2016 with final data due 2Q 2017.
GEN-1 OVATION
Ovarian cancer

Latest News

  1. Celsion Corporation Announces Stock Consolidation
  2. Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
  3. Edited Transcript of CLSN earnings conference call or presentation 12-May-17 3:00pm GMT
  4. Investor Network: Celsion Corporation to Host Earnings Call
  5. Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update
  6. Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017
  7. Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Cancer Patients
  8. ETFs with exposure to Celsion Corp. : April 27, 2017
  9. Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting
  10. Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia
  11. Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
  12. Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update
  13. Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
  14. Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017
  15. Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
  16. Celsion Corp. Cancer Medications Insider Buying and Analysis
  17. ETFs with exposure to Celsion Corp. : January 19, 2017